Hemodiyaliz tedavisi alan hastalarda serum Isı Şok Proteini B7 (HSPB7) ve tetranektin düzeylerinin belirlenmesi

Yıl 2024, , 337 - 345, 01.04.2024

Özgen Kılıç Erkek , Gülşah Gündoğdu , Davut Akın , Mehmet Alpua , Dilek Sayın , Z. Melek Bor Küçükatay

https://doi.org/10.31362/patd.1409090

Öz

gelişebilmektedir. Isı şok proteini B7 (HSPB7) ve tetranektin proteinlerinin serum düzeyleri kalp kasında gelişen hasarı takiben değişmektedir. Bu çalışmada, HD tedavisi alan KBH hastalarında HSPB7 ve tetranektin düzeylerinin araştırılması amaçlanmıştır.
Gereç ve yöntem: Çalışmaya 30-60 yaş, sağlıklı ve HD hastası denekler katılmış olup iki grup oluşturulmuştur (n=60): Kontrol grubu (n=30) ve Hasta grubu (n=30). Hastaneye check-up için başvuran sağlıklı deneklerden ve böbrek hastalığı olup HD tedavisi alan hastalardan kan örnekleri alınmıştır. Alınan kanlardan biyokimyasal parametreler incelenmiştir. İzole edilen serum örneklerinden HSPB7 ve tetranektin düzeyleri solid faz sandwich (ELİSA) prensibine dayanan ölçüm kitleri kullanılarak belirlenmiştir.
Bulgular: Deneklerin cinsiyet, yaş, glukoz ve Demir (Fe) değerlerinde gruplar arasında anlamlı fark saptanmamıştır (p>0,05). Lenfosit, trombosit sayıları, hemoglobin ve albümin değerleri diyaliz hastalarında kontrol grubuna kıyasla düşük bulunmuştur (p<0,05). Diyaliz hastalarında üre, kreatin kinaz ve CRP değerleri sağlıklı kontrol grubuna göre yüksek saptanmıştır (p<0,05). Hastalarda sağlıklı deneklere kıyasla, HSPB7 düzeylerinde anlamlı artış ve tetranektin düzeylerinde ise anlamlı düşüş tespit edilmiştir (p<0,001).
Sonuç: Bu çalışmada, diyaliz tedavisi alan KBH hastalarında HSPB7 ve tetranektin düzeylerinde tespit edilen değişimler, böbrek yetmezliği olan hastalarda olası gelişebilecek kardiyovasküler hastalıkların gelişiminin erken göstergesi olabilir.

Anahtar Kelimeler

Hemodiyaliz, kronik böbrek hastalığı (KBH), HSPB7, tetranektin

Determining the levels of serum Heat Shock Protein B7 (HSPB7) and tetranectin in patients undergoing hemodialysis

Öz

Purpose: Heart damage may develop over time in patients with chronic renal disease (CKD), who are undergoing hemodialysis (HD) treatment. Serum levels of heat shock protein B7 (HSPB7) and tetranectin proteins change following damage to the heart muscle. This study aimed to determine HSPB7 and tetranectin levels in patients with CKD undergoing HD treatment.
Materials and methods: The patients aged 30-60 years old, healthy controls (n=30) and HD patients (n=30) participated in the study. Blood samples were taken from healthy subjects who applied to the hospital for check-up and from patients with kidney disease receiving HD treatment. Biochemical parameters were examined from the blood taken. HSPB7 and tetranectin levels from isolated serum samples were determined using measurement kits based on the solid phase sandwich (ELISA) principle.
Results: There was no significant difference between the groups in gender, age, glucose and iron (Fe) values of the subjects (p>0.05). Lymphocyte, platelet counts, hemoglobin and albumin values were found to be lower in patient group compared to the control group (p<0.05). Urea, creatine kinase (CK) and C-reactive protein (CRP) values were found to be higher in patient group than in the control group (p<0.05). A significant increase in HSPB7 levels and a significant decrease in tetranectin levels were detected in patient group compared to control group (p<0.001).
Conclusions: In this study, the changes detected in HSPB7 and tetranectin levels in with CKD undergoing HD treatment. May be early indicators of the possible development of cardiovascular diseases in patients with renal disease.

Anahtar Kelimeler

Hemodialysis, chronic renal disease (CKD), HSPB7, tetranectin

Etik Beyan

Ethical approval was obtained from the Pamukkale University Non-Interventional Ethics Committee with the approval number 13.09.2022/13 and E-60116787-020-263897 dated.

Kaynakça

• 1. Okpechi IG, Nthite T, Swanepoel CR. Health-related quality of life in patients on hemodialysis and peritoneal dialysis. Saudi J Kidney Dis Transpl 2013;24:519-526. https://doi.org/10.4103/1319-2442.111036
• 2. Vaidya SR, Aeddula NR. Chronic Kidney Disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. 2022 Oct 24.
• 3. Elliott DA. Hemodialysis. Clin Tech Small Anim Pract 2000;15:136-148. https://doi.org/10.1053/svms.2000.18297
• 4. Pedersen JO, Knudsen F, Jersild C. Acute effect of hemodialysis on neutrophil migration: impact on humoral and cellular function. Kidney Int Suppl 1988;24:86-89.
• 5. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000;356:147-152. https://doi.org/10.1016/S0140-6736(00)02456-9
• 6. Li X, Lindholm B. Cardiovascular risk prediction in chronic kidney disease. Am J Nephrol 2022;53:730-739. https://doi.org/10.1159/000528560
• 7. Cozzolino M, Galassi A, Pivari F, Ciceri P, Conte F. The cardiovascular burden in end-stage renal disease. Contrib Nephrol 2017;191:44-57. https://doi.org/10.1159/000479250
• 8. Ng CH, Ong ZH, Sran HK, Wee TB. Comparison of cardiovascular mortality in hemodialysis versus peritoneal dialysis. Int Urol Nephrol 2021;53:1363-1371. https://doi.org/10.1007/s11255-020-02683-9
• 9. Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012;380:1649-1661. https://doi.org/10.1016/S0140-6736(12)61272-0
• 10. Janowska MK, Baughman HER, Woods CN, Klevit RE. Mechanisms of small heat shock proteins. Cold Spring Harb Perspect Biol 2019;11:a034025(e1-22). https://doi.org/10.1101/CSHPERSPECT.A034025
• 11. Juo LY, Liao WC, Shih YL, Yang BY, Liu AB, Yan YT. HSPB7 interacts with dimerized FLNC and its absence results in progressive myopathy in skeletal muscles. J Cell Sci 2016;129:1661-1670. https://doi.org/10.1242/jcs.179887
• 12. Sun Y, MacRae TH. The small heat shock proteins and their role in human disease. FEBS J 2005;272:2613-2627. https://doi.org/10.1111/j.1742-4658.2005.04708.x
• 13. Rusmini P, Cristofani R, Galbiati M, et al. The role of the heat shock protein B8 (HSPB8) in motoneuron diseases. Front Mol Neurosci 2017;21:10:176(e1-9). https://doi.org/10.3389/FNMOL.2017.00176
• 14. Juo LY, Liao WC, Shih YL, et al. HSPB7 interacts with dimerized FLNC and its absence results in progressive myopathy in skeletal muscles. J Cell Sci 2016;129:1661-1670. https://doi.org/10.1242/jcs.179887
• 15. Chiu TF, Li CH, Chen CC, et al. Association of plasma concentration of small heat shock protein B7 with acute coronary syndrome. Circ J 2012;76:2226-2233. https://doi.org/10.1253/circj.cj-12-0238
• 16. Chen FF, Xia YL, Xu CQ, et al. Common variant rs7597774 in ADD2 is associated with dilated cardiomyopathy in Chinese Han population. Int J Clin Exp Med 2015;8:1188-1196.
• 17. Tanisawa K, Arai Y, Hirose N, et al. Exome-wide association study ıdentifies clec3b missense variant p.s106g as being associated with extreme longevity in east asian populations. J Gerontol A Biol Sci Med Sci 2017;72:309-318. https://doi.org/10.1093/GERONA/GLW074
• 18. Christensen L, Clemmensen I. Differences in tetranectin immunoreactivity between benign and malignant breast tissue. Histochemistry 1991;95:427-433. https://doi.org/10.1007/BF00315737
• 19. Arellano Garcia ME, Li R, Liu X, et al. Identification of tetranectin as a potential biomarker for metastatic oral cancer. Int J Mol Sci 2010;11:3106-3121. https://doi.org/10.3390/IJMS11093106
• 20. Dardé VM, De La Cuesta F, Gil Dones F, Alvarez Llamas G, Barderas MG, Vivanco F. Analysis of the plasma proteome associated with acute coronary syndrome: Does a permanent protein signature exist in the plasma of ACS patients? J Proteome Res 2010;9:4420-4432. https://doi.org/10.1021/pr1002017
• 21. Ghazavi A, Ganji A, Keshavarzian N, Rabiemajd S, Mosayebi G. Cytokine profile and disease severity in patients with COVID-19. Cytokine 2021;137:155323. https://doi.org/10.1016/j.cyto.2020.155323
• 22. Khan Z, Pandey M. Role of kidney biomarkers of chronic kidney disease: an update. Saudi J Biol Sci 2014;21:294-299. https://doi.org/10.1016/J.SJBS.2014.07.003
• 23. Wang Y, Gao L. Inflammation and cardiovascular disease associated with hemodialysis for end-stage renal disease. Front Pharmacol 2022;13:800950(e1-19). https://doi.org/10.3389/FPHAR.2022.800950
• 24. Alanli R, Kucukay MB, Mursel S, et al. Laboratory test paramaters and echocardiography findings that affect mortality in hemodialysis patients. Ankara Egt Ars Hast Derg 2022;56:74-77. https://doi.org/10.20492/aeahtd.1019834
• 25. Ma L, Zhao S. Risk factors for mortality in patients undergoing hemodialysis: A systematic review and meta-analysis. Int J Cardiol 2017;238:151-158. https://doi.org/10.1016/j.ijcard.2017.02.095
• 26. Jaffe AS, Ritter C, Meltzer V, Harter H, Roberts R. Unmasking artifactual increases in creatine kinase isoenzymes in patients with renal failure. J Lab Clin Med 1984;104:193-202.
• 27. Moro García MA, Mayo JC, Sainz RM, Alonso Arias R. Influence of Inflammation in the Process of T Lymphocyte Differentiation: Proliferative, Metabolic, and Oxidative Changes. Front Immunol 2018;9:00339(e1-18). https://doi.org/10.3389/FIMMU.2018.00339
• 28. Hakim RM, Schafer AI. Hemodialysis-associated platelet activation and thrombocytopenia. Am J Med 1985;78:575-580. https://doi.org/10.1016/0002-9343(85)90398-5
• 29. Buchanan C, Mohammed A, Cox E, et al. Intradialytic cardiac magnetic resonance imaging to assess cardiovascular responses in a short-term trial of hemodiafiltration and hemodialysis. J Am Soc Nephrol 2017:28:1269-1277. https://doi.org/10.1681/ASN.2016060686
• 30. Kanda H, Hirasaki Y, Iida T, Kanao Kanda M, Toyama Y, Chiba T, Kunisawa T. Perioperative management of patients with end-stage renal disease. J Cardiothorac Vasc Anesth 2017;31:2251-2267. https://doi.org/10.1053/j.jvca.2017.04.019
• 31. Morimoto RI. Cell-nonautonomous regulation of proteostasis in aging and disease. Cold Spring Harb Perspect Biol 2020;12:a034074. https://doi.org/10.1101/CSHPERSPECT.A034074
• 32. Doran P, Gannon J, O’Connell K, Ohlendieck K. Aging skeletal muscle shows a drastic increase in the small heat shock proteins αB-crystallin/HspB5 and cvHsp/HspB7. Eur J Cell Biol 2007;86:629-640. https://doi.org/10.1016/j.ejcb.2007.07.003
• 33. Muranova LK, Shatov VM, Bukach OV, Gusev NB. Cardio-Vascular Heat Shock Protein (cvHsp, HspB7), an unusual representative of small heat shock protein family. Biochemistry (Moscow) 2021;86:1-11. https://doi.org/10.1134/S0006297921140017
• 34. Rosenfeld GE, Mercer EJ, Mason CE, Evans T. Small heat shock proteins Hspb7 and Hspb12 regulate early steps of cardiac morphogenesis. Dev Biol 2013;381:389-400. https://doi.org/10.1016/J.YDBIO.2013.06.025
• 35. Liu L, Zhang X, Qian B, et al. Over-expression of heat shock protein 27 attenuates doxorubicin-induced cardiac dysfunction in mice. Eur J Heart Fail 2007;9:762-769. https://doi.org/10.1016/j.ejheart.2007.03.007
• 36. Liao WC, Juo LY, Shih YL, Chen YH, Yan YT. HSPB7 prevents cardiac conduction system defect through maintaining intercalated disc integrity. PLoS Genet 2017;13:e1006984. https://doi.org/10.1371/JOURNAL.PGEN.1006984
• 37. Mogues T, Etzerodt M, Hall C, Engelich G, Graversen JH, Hartshorn KL. Tetranectin Binds to the Kringle 1-4 Form of Angiostatin and Modifies Its Functional Activity. J Biomed Biotechnol 2004;2004:73-78. https://doi.org/10.1155/S1110724304307096
• 38. Jaquinod M, Las Holtet T, Etzerodt M, Clemmensen I, Thøgersen HC, Roepstorff P. Mass spectrometric characterisation of post-translational modification and genetic variation in human tetranectin. Biol Chem 1999;380:1307-1314. https://doi.org/10.1515/BC.1999.166
• 39. Yin X, Subramanian S, Hwang SJ, et al. Protein biomarkers of new-onset cardiovascular disease: a prospective study from the Systems Approach to Biomarker Research in Cardiovascular Disease (SABRe CVD) initiative. Arterioscler Thromb Vasc Biol 2014;34:939-945. https://doi.org/10.1161/ATVBAHA.113.302918
• 40. Chen Y, Han H, Yan X, et al. Tetranectin as a potential biomarker for stable coronary artery disease. Sci Rep 2015;1:17632. https://doi.org/10.1038/SREP17632